JP6437559B2 - Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン - Google Patents
Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン Download PDFInfo
- Publication number
- JP6437559B2 JP6437559B2 JP2016541294A JP2016541294A JP6437559B2 JP 6437559 B2 JP6437559 B2 JP 6437559B2 JP 2016541294 A JP2016541294 A JP 2016541294A JP 2016541294 A JP2016541294 A JP 2016541294A JP 6437559 B2 JP6437559 B2 JP 6437559B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- amino
- group
- dichlorophenyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VLOJEWGCECYEAM-UHFFFAOYSA-N CC1(C=CC(Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)=CC1)N1C(C2)CNC2C1 Chemical compound CC1(C=CC(Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)=CC1)N1C(C2)CNC2C1 VLOJEWGCECYEAM-UHFFFAOYSA-N 0.000 description 1
- YUPAEYHVCOZVOK-MDYZWHIJSA-N CC1(C=CC(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)=CC1)N1[C@H](CO)CN(C)CC1 Chemical compound CC1(C=CC(Nc(nc2N(C)CN3c(c(Cl)ccc4)c4Cl)ncc2C3=O)=CC1)N1[C@H](CO)CN(C)CC1 YUPAEYHVCOZVOK-MDYZWHIJSA-N 0.000 description 1
- 0 CN(C(*)(*)N1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CCNCC2)nc2)c2C1=O Chemical compound CN(C(*)(*)N1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CCNCC2)nc2)c2C1=O 0.000 description 1
- TYNDDJWXWHJULJ-UHFFFAOYSA-N CN(CC1)CCC1Oc(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O Chemical compound CN(CC1)CCC1Oc(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O TYNDDJWXWHJULJ-UHFFFAOYSA-N 0.000 description 1
- HKRAKIIDROVHCU-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N(CC2)CCS2(=O)=O)nc2)c2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N(CC2)CCS2(=O)=O)nc2)c2C1=O HKRAKIIDROVHCU-UHFFFAOYSA-N 0.000 description 1
- PIUTZCHAHKDSNS-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CNCC(F)(F)F)c3N3CCNCC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)cc(CNCC(F)(F)F)c3N3CCNCC3)ncc2C1=O PIUTZCHAHKDSNS-UHFFFAOYSA-N 0.000 description 1
- ZDMVUMOTHMZRQP-UHFFFAOYSA-N CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3CCN(CC(O)=O)CC3)ncc2C1=O Chemical compound CN(CN1c(c(Cl)ccc2)c2Cl)c2nc(Nc(cc3)ccc3N3CCN(CC(O)=O)CC3)ncc2C1=O ZDMVUMOTHMZRQP-UHFFFAOYSA-N 0.000 description 1
- LTHCLGLQFVDPSF-UHFFFAOYSA-N CN(CN1c(c(F)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CC(COC)NCC2)nc2)c2C1=O Chemical compound CN(CN1c(c(F)ccc2)c2Cl)c(nc(Nc(cc2)ccc2N2CC(COC)NCC2)nc2)c2C1=O LTHCLGLQFVDPSF-UHFFFAOYSA-N 0.000 description 1
- SZLLSOCIXPGJLW-WMZOPIPTSA-N CN(CN1c(cccc2)c2Cl)c(nc(Nc(cc2)ccc2N2[C@@H](C3)CN[C@@H]3C2)nc2)c2C1=O Chemical compound CN(CN1c(cccc2)c2Cl)c(nc(Nc(cc2)ccc2N2[C@@H](C3)CN[C@@H]3C2)nc2)c2C1=O SZLLSOCIXPGJLW-WMZOPIPTSA-N 0.000 description 1
- QZJJZINNSZRIHM-UHFFFAOYSA-N CN1CCN(Cc(cc2)ccc2Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)CC1 Chemical compound CN1CCN(Cc(cc2)ccc2Nc(nc2)nc(N(C)CN3c(c(Cl)ccc4)c4Cl)c2C3=O)CC1 QZJJZINNSZRIHM-UHFFFAOYSA-N 0.000 description 1
- KORCVBOCKBZMRD-MRXNPFEDSA-N C[C@H](C1)N(C)CCN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O Chemical compound C[C@H](C1)N(C)CCN1c(cc1)ccc1Nc(nc1)nc(N(C)CN2c(c(Cl)ccc3)c3Cl)c1C2=O KORCVBOCKBZMRD-MRXNPFEDSA-N 0.000 description 1
- KVQJFGGAQBGGCB-MRXNPFEDSA-N C[C@H](C1)NCCN1c(c(COC)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@H](C1)NCCN1c(c(COC)c1)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O KVQJFGGAQBGGCB-MRXNPFEDSA-N 0.000 description 1
- SAVKMENYJBWNHC-CQSZACIVSA-N C[C@H](C1)NCCN1c(cc1F)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O Chemical compound C[C@H](C1)NCCN1c(cc1F)ccc1Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O SAVKMENYJBWNHC-CQSZACIVSA-N 0.000 description 1
- ZOKGXCGRFOEAGH-CQSZACIVSA-N C[C@H](C1)NCCN1c(ccc(Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)c1)c1F Chemical compound C[C@H](C1)NCCN1c(ccc(Nc(nc1N(C)CN2c(c(Cl)ccc3)c3Cl)ncc1C2=O)c1)c1F ZOKGXCGRFOEAGH-CQSZACIVSA-N 0.000 description 1
- ZSQBZADJUMJJAA-UHFFFAOYSA-N O=C(c1c(N2C3CCC2)nc(Nc(cc2)ccc2N2CCNCC2)nc1)N3c(c(Cl)ccc1)c1Cl Chemical compound O=C(c1c(N2C3CCC2)nc(Nc(cc2)ccc2N2CCNCC2)nc1)N3c(c(Cl)ccc1)c1Cl ZSQBZADJUMJJAA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1322602.2 | 2013-12-19 | ||
| GBGB1322602.2A GB201322602D0 (en) | 2013-12-19 | 2013-12-19 | Pharmaceutical compounds |
| PCT/GB2014/053793 WO2015092431A1 (en) | 2013-12-19 | 2014-12-19 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500335A JP2017500335A (ja) | 2017-01-05 |
| JP6437559B2 true JP6437559B2 (ja) | 2018-12-12 |
Family
ID=50071157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541294A Active JP6437559B2 (ja) | 2013-12-19 | 2014-12-19 | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン |
Country Status (28)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10364247B2 (en) * | 2015-04-21 | 2019-07-30 | Ruijin Hospital Affiliated To Shanghai Jiao Tong University School Of Medicine | Preparation and use of novel protein kinase inhibitors |
| CA3003737C (en) * | 2015-11-01 | 2021-09-14 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of making and using the same |
| US10703759B2 (en) | 2016-11-16 | 2020-07-07 | Impact Therapeutics, Inc | 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| US10954253B2 (en) | 2017-01-23 | 2021-03-23 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor |
| GB201703881D0 (en) * | 2017-03-10 | 2017-04-26 | Almac Discovery Ltd | Pharmaceutical compounds |
| EP3600247A1 (en) | 2017-03-31 | 2020-02-05 | Seattle Genetics, Inc. | Combinations of chk1- and wee1 - inhibitors |
| US11345710B2 (en) | 2017-07-10 | 2022-05-31 | Impact Therapeutics (Shanghai), Inc | Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof |
| WO2019037678A1 (zh) * | 2017-08-24 | 2019-02-28 | 上海迪诺医药科技有限公司 | 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用 |
| US11299493B2 (en) | 2017-10-09 | 2022-04-12 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| US10807994B2 (en) | 2017-10-09 | 2020-10-20 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| RS65901B1 (sr) | 2017-11-01 | 2024-09-30 | Wuxi Biocity Biopharmaceutics Co Ltd | Makrociklično jedinjenje koje služi kao wee1 inhibitor i primene istog |
| US12220415B2 (en) | 2018-02-28 | 2025-02-11 | The Regents Of The University Of Colorado, A Body Corporate | WEE1 kinase inhibitors and methods of treating cancer using the same |
| EA202190885A1 (ru) * | 2018-09-27 | 2021-06-25 | Бетта Фармасьютикалз Ко., Лтд | Ингибитор fgfr4 и его применение |
| EP3875460A4 (en) | 2018-10-26 | 2022-07-20 | Wuxi Biocity Biopharmaceutics Co., Ltd. | PYRIMIDINDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF |
| AU2019413360B2 (en) | 2018-12-28 | 2025-05-22 | Spv Therapeutics Inc. | Cyclin-dependent kinase inhibitors |
| US20220194960A1 (en) | 2019-03-22 | 2022-06-23 | Shouyao Holdings (beijing) Co., Ltd. | Wee1 inhibitor and preparation and use thereof |
| EP3952879A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| JP2022526831A (ja) | 2019-04-09 | 2022-05-26 | ニューベイション・バイオ・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| FI3964510T3 (fi) | 2019-04-30 | 2024-07-24 | Wuxi Biocity Biopharmaceutics Co Ltd | Wee1-inhibiittoriyhdisteen kidemuoto ja sen käyttö |
| CN112142763B (zh) * | 2019-06-28 | 2024-01-26 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| US20230159540A1 (en) | 2020-06-17 | 2023-05-25 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | PYRAZOLO[3,4-d]PYRIMIDIN-3-ONE DERIVATIVE AS WEE-1 INHIBITOR |
| US20230416247A1 (en) * | 2020-10-01 | 2023-12-28 | University Of Washington | Drug-like molecules and methods for the therapeutic targeting of microrna-21 |
| WO2022129281A1 (en) * | 2020-12-18 | 2022-06-23 | Glaxosmithkline Intellectual Property Development Limited | Nitrogen containing 2,3-dihydroquinazolinone compounds as nav1.8 inhibitors |
| EP4262978A1 (en) * | 2020-12-18 | 2023-10-25 | GlaxoSmithKline Intellectual Property Development Limited | Chemical compounds useful for inhibiting nav1.8 voltage-gated sodium channels and treating nav1.8 mediated diseases |
| AU2022265032A1 (en) | 2021-04-30 | 2023-11-16 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
| AU2022297176A1 (en) | 2021-06-25 | 2024-01-04 | Korea Research Institute Of Chemical Technology | Novel bifunctional heterocyclic compound having btk degradation function via ubiquitin proteasome pathway, and use thereof |
| CN116462687B (zh) | 2022-01-18 | 2025-01-07 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| CN116836184B (zh) * | 2022-03-25 | 2025-07-25 | 药雅科技(上海)有限公司 | Wee1激酶抑制剂的制备及其应用 |
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| CN117402162A (zh) | 2022-07-13 | 2024-01-16 | 江苏天士力帝益药业有限公司 | Wee1抑制剂及其制备和用途 |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7504396B2 (en) | 2003-06-24 | 2009-03-17 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| SG150544A1 (en) | 2004-03-15 | 2009-03-30 | Hoffmann La Roche | Novel dichloro-phenyl-pyrido [2,3-d] pyrimidine derivatives, their manufacture and use as pharmaceutical agents |
| FR2896246B1 (fr) | 2006-01-13 | 2008-08-15 | Sanofi Aventis Sa | Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique. |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| US8198281B2 (en) | 2007-04-25 | 2012-06-12 | Merck Sharp & Dohme Corp. | Crystalline forms of dihydropyrazolopyrimidinone |
| PT2168966T (pt) | 2007-06-15 | 2017-01-02 | Msd Kk | Derivado de bicicloanilina |
| CA2703489A1 (en) * | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | Pyridone-substituted-dihydropyrazolopyrimidinone derivative |
| AU2009325398A1 (en) * | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivative |
| CA2745959A1 (en) | 2008-12-12 | 2010-06-17 | Msd K.K. | Dihydropyrimidopyrimidine derivatives |
| JP5886310B2 (ja) * | 2010-12-06 | 2016-03-16 | グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ | Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物 |
| WO2012085167A1 (en) | 2010-12-22 | 2012-06-28 | Merz Pharma Gmbh & Co. Kgaa | Metabotropic glutamate receptor modulators |
| TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| WO2013013031A1 (en) * | 2011-07-19 | 2013-01-24 | Abbvie Inc. | Pyridazino [4, 5 -d] pyrimidin- (6h) -one inhibitors of wee - 1 kinase |
| EP2776434A1 (en) | 2011-10-20 | 2014-09-17 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| ES2606640T3 (es) * | 2012-02-23 | 2017-03-24 | Abbvie Inc. | Inhibidores de cinasas de tipo piridopirimidinona |
| CN102816164A (zh) * | 2012-08-31 | 2012-12-12 | 北京理工大学 | 一种合成7-氨基-2,3-二氢嘧啶[4,5-d]嘧啶-4(1H)-酮的方法 |
-
2013
- 2013-12-19 GB GBGB1322602.2A patent/GB201322602D0/en not_active Ceased
-
2014
- 2014-12-19 EP EP14815843.9A patent/EP3083625B1/en active Active
- 2014-12-19 SI SI201430580T patent/SI3083625T1/en unknown
- 2014-12-19 JP JP2016541294A patent/JP6437559B2/ja active Active
- 2014-12-19 MX MX2016007801A patent/MX371108B/es active IP Right Grant
- 2014-12-19 BR BR112016014151-2A patent/BR112016014151B1/pt active IP Right Grant
- 2014-12-19 RS RS20171338A patent/RS56731B1/sr unknown
- 2014-12-19 ES ES14815843.9T patent/ES2650013T3/es active Active
- 2014-12-19 PL PL14815843T patent/PL3083625T3/pl unknown
- 2014-12-19 NZ NZ720178A patent/NZ720178A/en unknown
- 2014-12-19 CN CN201480069437.9A patent/CN105829315B/zh active Active
- 2014-12-19 DK DK14815843.9T patent/DK3083625T3/en active
- 2014-12-19 SG SG11201603814TA patent/SG11201603814TA/en unknown
- 2014-12-19 WO PCT/GB2014/053793 patent/WO2015092431A1/en not_active Ceased
- 2014-12-19 CA CA2933755A patent/CA2933755C/en active Active
- 2014-12-19 PT PT148158439T patent/PT3083625T/pt unknown
- 2014-12-19 LT LTEP14815843.9T patent/LT3083625T/lt unknown
- 2014-12-19 HU HUE14815843A patent/HUE037908T2/hu unknown
- 2014-12-19 SM SM20180020T patent/SMT201800020T1/it unknown
- 2014-12-19 KR KR1020167019551A patent/KR102405462B1/ko active Active
- 2014-12-19 NO NO14815843A patent/NO3083625T3/no unknown
- 2014-12-19 US US15/105,869 patent/US9850247B2/en active Active
- 2014-12-19 RU RU2016123363A patent/RU2691105C1/ru active
- 2014-12-19 HR HRP20180080TT patent/HRP20180080T1/hr unknown
- 2014-12-19 AU AU2014369457A patent/AU2014369457B2/en active Active
-
2016
- 2016-05-17 ZA ZA2016/03337A patent/ZA201603337B/en unknown
- 2016-05-17 IL IL245672A patent/IL245672B/en unknown
-
2018
- 2018-01-15 CY CY20181100041T patent/CY1120035T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6437559B2 (ja) | Ｗｅｅ−１キナーゼ阻害剤として有用なピリミドピリミジノン | |
| JP7073359B2 (ja) | ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体 | |
| US10766902B2 (en) | Wee-1 inhibiting pyrazolopyrimidinone compounds | |
| CN102548557B (zh) | 用于降低β-淀粉状蛋白生成的化合物 | |
| TWI624467B (zh) | 選擇性經取代之喹啉化合物 | |
| CN104470925A (zh) | 作为激酶抑制剂的咪唑并三嗪甲腈 | |
| EP3166608A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| WO2024153155A1 (zh) | 双杂环wrn抑制剂、其制备方法及其应用 | |
| JP7760622B2 (ja) | 皮膚病変の治療 | |
| WO2019125798A1 (en) | Carbamate and urea compounds as multikinase inhibitors | |
| CN111747954B (zh) | 吡嗪化合物和其用途 | |
| HK1227877B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK1227877A1 (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| HK40037929A (en) | Pyrazine compounds and uses thereof | |
| HK40037929B (en) | Pyrazine compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20161102 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20161102 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170919 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180627 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180927 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181023 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181114 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6437559 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |